Astrocytes protect glioma cells from chemotherapy and upregulate survival genes via gap junctional communication

Molecular Medicine Reports

Volumn 13, Issue 2, 2016, Pages 1329-1335

  Lin, Qingtang ^a   Liu, Zhao ^a   Ling, Feng ^a   Xu, Geng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Astrocytes; Chemotherapy; Gap junctional communication; Glioma cells; Protection; Survival genes

Indexed keywords

CISPLATIN; FLUORESCEIN ISOTHIOCYANATE; FLUOROURACIL; CONNEXIN 43;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL COMMUNICATION; CELL CONTACT; CELL INFILTRATION; CELL PROTECTION; CHEMOTHERAPY; CONTROLLED STUDY; FLOW CYTOMETRY; GAP JUNCTION; GENE EXPRESSION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; SCANNING ELECTRON MICROSCOPY; UPREGULATION; BRAIN; BRAIN NEOPLASMS; COCULTURE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; ULTRASTRUCTURE;

ASTROCYTES; BRAIN; BRAIN NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CONNEXIN 43; GAP JUNCTIONS; GLIOMA; HUMANS; MICROSCOPY, ELECTRON, SCANNING; TRANSCRIPTIONAL ACTIVATION;

EID: 84956902561     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4680     Document Type: Article

References (37)

1. Wrensch M, Minn Y, Chew T, Bondy M and Berger MS: Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro Oncol 4: 278-299, 2002.
2. Fisher JL, Schwartzbaum JA, Wrensch M and Wiemels JL: Epidemiology of brain tumors. Neurol Clin 25: 867-890, 2007.
3. Lévy S, Chapet S and Mazeron JJ: Management of gliomas. Cancer Radiother 18: 461-467, 2014.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
5. Ashmore SM, Thomas DG and Darling JL: Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma? Anticancer Drugs 10: 861-872, 1999.
6. Jennings MT and Iyengar S: The molecular genetics of therapeutic resistance in malignant astrocytomas. Am J Pharmacogenomics 1: 93-99, 2001.
7. Shapiro WR and Shapiro JR: Principles of brain tumor chemotherapy. Semin Oncol 13: 56-69, 1986.
8. Mousseau M: Chemotherapy of brain tumors: Biological basis of its limited efficacy. Bull Cancer 81: 414-424, 1994 (In French).
9. Stewart DJ: A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 20: 121-139, 1994.
10. Zhang RD, Price JE, Fujimaki T, Bucana CD and Fidler IJ: Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 141: 1115-1124, 1992.
11. Hoelzinger DB, Demuth T and Berens ME: Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99: 1583-1593, 2007.
12. Fidler IJ: The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
13. Abbott NJ, Rönnbäck L and Hansson E: Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7: 41-53, 2006.
14. Fields RD and Stevens-Graham B: New insights into neuron-glia communication. Science 298: 556-562, 2002.
15. Bullock TH, Bennett MV, Johnston D, Josephson R, Marder E and Fields RD: Neuroscience: The neuron doctrine, redux. Science 310: 791-793, 2005.
16. Miller G: Neuroscience: The dark side of glia. Science 308: 778-781, 2005.
17. Allen NJ and Barres BA: Neuroscience: Glia-more than just brain glue. Nature 457: 675-677, 2009.
18. Sofroniew MV: Reactive astrocytes in neural repair and protection. Neuroscientist 11: 400-407, 2005.
19. Crooks DA, Scholtz CL, Vowles G, Greenwald S and Evans S: The glial reaction in closed head injuries. Neuropathol Appl Neurobiol 17: 407-411, 1991.
20. Mahesh VB, Dhandapani KM and Brann DW: Role of astrocytes in reproduction and neuroprotection. Mol Cell Endocrinol 246: 1-9, 2006.
21. Chen LW, Yung KL and Chan YS: Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease. Curr Drug Targets 6: 821-833, 2005.
22. Krysko DV, Leybaert L, Vandenabeele P and D'Herde K: Gap junctions and the propagation of cell survival and cell death signals. Apoptosis 10: 459-469, 2005.
23. Lin JH, Weigel H, Cotrina ML, Liu S, Bueno E, Hansen AJ, Hansen TW, Goldman S and Nedergaard M: Gap-junction-mediated propagation and amplification of cell injury. Nat Neurosci 1: 494-500, 1998.
24. Rouach N, Avignone E, Même W, Koulakoff A, Venance L, Blomstrand F and Giaume C: Gap junctions and connexin expression in the normal and pathological central nervous system. Biol Cell 94: 457-475, 2002.
25. Zhang W, Couldwell WT, Simard MF, Song H, Lin JH and Nedergaard M: Direct gap junction communication between malignant glioma cells and astrocytes. Cancer Res 59: 1994-2003, 1999.
26. Zhou B, Bu G, Zhou Y, Zhao Y, Li W and Li M: Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis and increases chemosensitivity to temozolomide in glioblastoma cells. Med Oncol 32: 378, 2015.
27. Chai KM, Wang CY, Liaw HJ, Fang KM, Yang CS and Tzeng SF: Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide. Oncotarget 5: 10901-10915, 2014.
28. Langley RR, Fan D, Guo L, Zhang C, Lin Q, Brantley EC, McCarty JH and Fidler IJ: Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis. Int J Oncol 35: 665-672,2009.
29. Grossman R, Brastianos H, Blakeley JO, Mangraviti A, Lal B, Zadnik P, Hwang L, Wicks RT, Goodwin RC, Brem H and Tyler B: Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. J Neurooncol 116: 59-65, 2014.
30. Peng Q, Moan J, Ma LW and Nesland JM: Uptake, localization and photodynamic effect of meso-tetra (hydroxyphenyl) porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma. Cancer Res 55: 2620-2626, 1995.
31. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ and Hung MC: Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13: 385-393, 2008.
32. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003.
33. Hinkerohe D, Wolfkühler D, Haghikia A, Meier C, Faustmann PM and Schlegel U: Dexamethasone differentially regulates functional membrane properties in glioma cell lines and primary astrocytes in vitro. J Neurooncol 103: 479-489, 2011.
34. Zhang B, Feng X, Wang J, Xu X, Liu H and Lin N: Adenovirus-mediated delivery of bFGF small interfering RNA increases levels of connexin 43 in the glioma cell line, U251. J Exp Clin Cancer Res 29: 3, 2010.
35. Goldberg GS, Moreno AP, Bechberger JF, Hearn SS, Shivers RR, MacPhee DJ, Zhang YC and Naus CC: Evidence that disruption of connexin particle arrangements in gap junction plaques is associated with inhibition of gap junctional communication by a glycyrrhetinic acid derivative. Exp Cell Res 222: 48-53, 1996.
36. Guan X, Wilson S, Schlender KK and Ruch RJ: Gap-junction disassembly and connexin 43 dephosphorylation induced by 18 beta-glycyrrhetinic acid. Mol Carcinog 16: 157-164, 1996.
37. Fidler IJ, Balasubramanian K, Lin Q, Kim SW and Kim SJ: The brain microenvironment and cancer metastasis. Mol Cells 30: 93-98, 2010.